Clinical Trials Browser

Has results × Neoplasms, Plasma Cell × Bortezomib × Clear all

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01208662 2026-01-22

DFCI 10-106

Phase 3 Active not recruiting

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Completed

95 enrolled 13 charts

LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

NCT00464178 2022-07-20

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

7 enrolled 5 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02424851 2022-01-27

OPTIMAL

Phase 2 Completed

31 enrolled 13 charts

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT00792142 2021-08-19

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Phase 2 Completed

45 enrolled 8 charts

Multiple Myeloma, Neurotoxicity Syndromes, Neoplasms, Plasma Cell

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Phase 3 Completed

637 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT00469209 2020-09-24

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Phase 1/2 Completed

60 enrolled 7 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00084747 2020-08-17

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Phase 1/2 Completed

30 enrolled 7 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00985907 2020-06-17

DMV

Phase 1/2 Terminated

13 enrolled 8 charts

Multiple Myeloma, Patient Participation, Neoplasms, Plasma Cell

NCT01023308 2020-03-17

PANORAMA-1

Phase 3 Completed

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01438177 2020-02-24

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

Phase 2 Terminated

11 enrolled 9 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00948922 2019-09-18

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Phase 2 Completed

124 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01315873 2018-02-07

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Phase 2 Terminated

24 enrolled 3 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00473590 2017-06-14

AMBER

Phase 2 Completed

102 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00523848 2017-02-23

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Phase 2 Completed

46 enrolled 8 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00458822 2016-08-10

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Phase 2 Completed

40 enrolled 5 charts

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00983346 2016-07-11

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

Phase 2 Terminated

17 enrolled 5 charts

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT00609167 2011-05-17

Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

63 enrolled 15 charts

Multiple Myeloma, Neoplasms, Plasma Cell